ReviewJournal of neurovirology2003
Development of a recombinant vaccine against Japanese encephalitis.
Review in Journal of neurovirology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Type I/type III IFN and related factors regulate JEV infection and BBB endothelial integrity.Journal of neuroinflammation · 2023Article
- Production of Plant-Derived Japanese Encephalitis Virus Multi-Epitope Peptide inInternational journal of molecular sciences · 2023Article
- Article
- Anticipating Emerging Mosquito-borne Flaviviruses in the USA: What Comes after Zika?Trends in parasitology · 2018Article
- Expression of domain III of the envelope protein from GP-78: a Japanese encephalitis virus.Virusdisease · 2017Article
- The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts.Drug discovery today · 2017Review
- Vaccine strategies for the control and prevention of Japanese encephalitis in Mainland China, 1951-2011.PLoS neglected tropical diseases · 2014Review
- Inactivated genotype 1 Japanese encephalitis vaccine for swine.Clinical and experimental vaccine research · 2014Article
- Japanese encephalitis: the virus and vaccines.Human vaccines & immunotherapeutics · 2014Review
- Antiviral activity of Rheum palmatum methanol extract and chrysophanol against Japanese encephalitis virus.Archives of pharmacal research · 2014Article
- Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response.Virology journal · 2012Article
- Antiviral Activity of Isatis indigotica Extract and Its Derived Indirubin against Japanese Encephalitis Virus.Evidence-based complementary and alternative medicine : eCAM · 2012Article
- Article
- Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.Virology journal · 2011Article
- Mutation of putative N-linked glycosylation sites in Japanese encephalitis virus premembrane and envelope proteins enhances humoral immunity in BALB/C mice after DNA vaccination.Virology journal · 2011Article
- Development of a vaccine to prevent Japanese encephalitis: a brief review.International journal of general medicine · 2009Article
- Japanese encephalitis-a pathological and clinical perspective.PLoS neglected tropical diseases · 2009Article
- Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin-proteasome system.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2009Article
- The prM-independent packaging of pseudotyped Japanese encephalitis virus.Virology journal · 2009Article
- Bellary, India achieves negligible case fatality due to Japanese encephalitis despite no vaccination: an outbreak investigation in 2004.Indian journal of pediatrics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Japanese encephalitis (JE) is the major form of viral encephalitis in much of the South-East Asia, India, and China. The disease is caused by a mosquito-borne virus known as Japanese encephalitis virus (JEV). The virus spreads in the form of epidemics, although several endemic areas for JEV activity are known. In recent years, JEV has spread to newer geographic locations such as Australia and Pakistan, and thus has become an important emerging virus infection in these areas. A mouse brain-derived, formalin-inactivated vaccine is available for immunization against JE. Because the formalin-inactivated JEV vaccine has limitations in terms of safety, availability, and cost, attempts are being made to develop improved vaccine using the recombinant DNA technology. This article reviews various attempts in this direction and summarizes the latest developments such as the recombinant yellow fever virus- or the plasmid DNA-based JEV vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.